A side-by-side comparison of two Healthcare investors: Catalio Capital Management (Power Score 82/100) and Novo Holdings (Power Score 83/100), both ranked among the most active firms tracked in this category.
| Catalio Capital Management | Novo Holdings | |
|---|---|---|
| Power Score™ | 82/100 | 83/100 |
| Assets Managed | $2B (the homepage prints "$2B In assets under management *as of 10/01/2025"; the raw date form is carried here because for a US filer 10/01/2025 reads as 1 October 2025) | €93B (approx.; DKK 694bn total assets under management at 31 December 2025, per the Novo Holdings Annual Report 2025, of which DKK 407bn is the holding in Novo Nordisk) |
| Founded | 2020 | 1999 |
| Headquarters | New York, NY | Hellerup, Denmark |
| Sectors | Healthcare, Biotech, Medical Devices, Diagnostics, Life Sciences, Data | Pharmaceuticals, Biotech, Medtech, Healthcare, Synthetic Biology, Climate, Deep Tech, Real Estate, Infrastructure |
Catalio Capital Management is an SEC-registered investment adviser (CRD 310374, SEC file 801-121976) that describes itself as focused on the full lifecycle of innovative healthcare investing, across private, public and credit markets. It runs four stated strategies: Private Equity and Venture Capital, investing in privately held innovative healthcare companies at all stages from inception to IPO; Structured Opportunities, providing senior-secured financing to healthcare innovators; Public Equities, a fundamental equity long/short strategy investing in global healthcare equities across innovative drugs, devices, diagnostics and data; and Co-Investments offering limited partners direct access to selected deals. The firm operates from New York, Washington DC and London, and states that it works with a network of more than 45 Venture Partners who hold equity interests across all Catalio strategies. It is a multi-strategy healthcare investment manager rather than a pure venture partnership.
View full Catalio Capital Management profile →Novo Holdings A/S is the holding and investment company of the Novo Nordisk Foundation, responsible for managing the Foundation's assets and wealth. Its stated purpose is to improve people's health and the sustainability of society and the planet by generating long-term returns on the Foundation's assets. Its work splits into two parts. First, it is the controlling shareholder of the Novo Group companies Novo Nordisk A/S and Novonesis A/S, holding more than 25 per cent of the ordinary share capital of each, including all the preferred A shares, and more than 70 per cent of the votes; the firm states its strategy is to be a stable and supportive owner of the Novo Group. Second, it runs an investment portfolio in two parts: Life Science Investments, made up of the Seed, Venture, Principal Investments, Planetary Health Investments and Asia teams, and Capital Investments, which manages equities, bonds, real estate, infrastructure and private equity, builds relationships with external equity and fixed income fund managers, and makes direct public equity and bond investments. The firm says it invests in almost all life science segments including pharmaceuticals, biotechnology, medical technology, healthcare services and industrial biosolutions, across North America, Europe and Asia. It is headquartered in Hellerup, Denmark, with offices in Boston, San Francisco, London, Singapore, Shanghai and Mumbai, and states that it employs more than 200 people and has made 180-plus direct investments.
View full Novo Holdings profile →